Chronic exposure to arsenic, estrogen, and their combination causes increased growth and transformation in human prostate epithelial cells potentially by hypermethylation-mediated silencing of MLH1

Prostate

Volumn 73, Issue 15, 2013, Pages 1660-1672

  Treas, Justin ^a   Tyagi, Tulika ^a   Singh, Kamaleshwar P ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

arsenic; epigenetics; estrogen; MLH1 hypermethylation; prostate cancer

Indexed keywords

ARSENIC; CYCLIN D1; ESTROGEN; MISMATCH REPAIR PROTEIN; PROTEIN BCL 2; PROTEIN MLH1; PROTEIN MSH4; PROTEIN MSH6; TRANSCRIPTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DNA EXTRACTION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; MALE; MALIGNANT TRANSFORMATION; MISMATCH REPAIR; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING;

ARSENIC; EPIGENETICS; ESTROGEN; MLH1 HYPERMETHYLATION; PROSTATE CANCER;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ARSENIC; CELL CYCLE; CELL ENLARGEMENT; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; ESTROGENS; GENE EXPRESSION; GENE SILENCING; HUMANS; MALE; METHYLATION; NUCLEAR PROTEINS; PROSTATE;

EID: 84884901780     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22701     Document Type: Article

References (49)

1. Stasiewicz D, Staroslawska E, Brzozowska A, Mocarska A, Losicki M, Szumilo J, Burdan F,. Epidemiology and risk factors of the prostate cancer. Pol Merkur Lekarski 2012; 33 (195): 163-167.
2. Wong YC, Wang XH, Ling MT,. Prostate development and carcinogenesis. Int Rev Cytol 2003; 227: 65-130.
3. Soto AM, Sonnenschein C,. Environmental causes of cancer: Endocrine disruptors as carcinogens. Nat Rev Endocrinol 2010; 6: 363-370.
4. Harkonen PL, Makela SI,. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 297-305.
5. Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, vom Saal FS,. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA 2005; 102: 7014-7019.
6. Prins GS, Birch L, Tang WY, Ho SM,. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol 2007; 23: 374-382.
7. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS,. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 2006; 66: 5624-5632.
8. Hu WY, Shi GB, Lam HM, Hu DP, Ho SM, Madueke IC, Kajdacsy-Balla A, Prins GS,. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology 2011; 152: 2150-2163.
9. Yu S, Zhang Y, Yuen MT, Zou C, Danielpour D, Chan FL,. 17-Beta-estradiol induces neoplastic transformation in prostatic epithelial cells. Cancer Lett 2011; 304: 8-20.
10. Bosland MC, Mahmoud AM,. Hormones and prostate carcinogenesis: Androgens and estrogens. J Carcinog 2011; 10: 33.
11. Ho SM, Lee MT, Lam HM, Leung YK,. Estrogens and prostate cancer: Etiology, mediators, prevention, and management. Endocrinol Metab Clin North Am 2011; 40: 591-614.
12. Lau KM, Leav I, Ho SM,. Rat estrogen receptor-alpha and -beta and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology 1998; 139 (1): 424-427.
13. Ling MT, Wang X, Ouyang XS, Lee TK, Fan TY, Xu K, Tsao SW, Wong YC,. Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene 2002; 21 (55): 8498-8505.
14. Nelles JL, Hu WY, Prins GS,. Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 2011; 6 (3): 437-451.
15. Treas JN, Tyagi T, Singh KP,. Effects of chronic exposure to arsenic and estrogen on epigenetic regulatory genes expression and epigenetic code in human prostate epithelial cells. PLoS ONE 2012; 7 (8): e43880.
16. Davey JC, Bodwell JE, Gosse JA, Hamilton JW,. Arsenic as an endocrine disruptor: Effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci 2007; 98: 75-86.
17. Benbrahim-Tallaa L, Webber MM, Waalkes MP,. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect 2007; 115 (20): 243-247.
18. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL,. Drinking water arsenic in Utah: A cohort mortality study. Environ Health Perspect 1999; 107 (5): 359-365.
19. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE,. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med 1999; 27: 1405-1412.
20. Singh KP, Kumari R, Treas J, DuMond JW,. Chronic exposure to arsenic causes increased cell survival, DNA damage, and increased expression of mitochondrial transcription factor A (mtTFA) in human prostate epithelial cells. Chem Res Toxicol 2011; 24 (3): 340-349.
21. Felty Q, Xiong WC, Sun D, Sarkar S, Singh KP, Parkash J, Roy D,. Estrogen-induced mitochondrial reactive oxygen species as signal-transducing messengers. Biochemistry 2005; 44 (18): 6900-6909.
22. Huang C, Ma WY, Li J, Goranson A, Dong Z,. Requirement of Erk, but not JNK, for arsenite-induced cell transformation. J Biol Chem 1999; 274 (21): 14595-14601.
23. Kaltreider RC, Pesce CA, Ihnat MA, Lariviere JP, Hamilton JW,. Differential effects of arsenic(III) and chromium(VI) on nuclear transcription factor binding. Mol Carcinog 1999; 25: 219-229.
24. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M,. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996; 15 (22): 6269-6279.
25. Ren X, McHale CM, Skibola CF, Smith AH, Smith MT, Zhang L,. An emerging role for epigenetic dysregulation in arsenic toxicity and carcinogenesis. Environ Health Perspect 2011; 119 (1): 11-19.
26. Huang C, Ke Q, Costa M, Shi X,. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem 2004; 255 (1-2): 57-66.
27. Reichard JF, Puga A,. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics 2010; 2 (1): 87-104.
28. Tapio S, Grosche B,. Arsenic in the aetiology of cancer. Mutat Res 2006; 612: 215-246.
29. Gupta RC,. Nonrandom binding of the carcinogen N-hydroxy-2- acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc Natl Acad Sci USA 1984; 81 (22): 6943-6947.
30. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
31. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR,. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001; 61 (22): 8135-8142.
32. Waalkes MP, Keefer LK, Diwan BA,. Induction of proliferative lesions of the uterus, testes, and liver in swiss mice given repeated injections of sodium arsenate: Possible estrogenic mode of action. Toxicol Appl Pharmacol 2000; 166 (1): 24-35.
33. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP,. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 2002; 94 (24): 1888-1891.
34. Wu CH, Tseng YS, Kao YT, Sheu HM, Liu HS,. Low concentration of arsenic-induced aberrant mitosis in keratinocytes through E2F1 transcriptionally regulated aurora-A. Toxicol Sci 2013; 132: 43-52.
35. Simeonova PP, Wang S, Toriuma W, Kommineni V, Matheson J, Unimye N, Kayama F, Harki D, Ding M, Vallyathan V, Luster MI,. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-1 transactivation. Cancer Res 2000; 60 (13): 3445-3453.
36. Saini MK, Sanyal SN,. PTEN regulates apoptotic cell death through PI3-K/Akt/GSK3beta signaling pathway in DMH induced early colon carcinogenesis in rat. Exp Mol Pathol 2012; 93: 135-146.
37. Sun Y, Kojima C, Chignell C, Mason R, Waalkes MP,. Arsenic transformation predisposes human skin keratinocytes to UV-induced DNA damage yet enhances their survival apparently by diminishing oxidant response. Toxicol Appl Pharmacol 2011; 255 (3): 242-250.
38. Bellacosa A,. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2001; 8 (11): 1076-1092.
39. Son BH, Ahn SH, Ko CD, Ka IW, Gong GY, Kim JC,. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J 2004; 10: 20-26.
40. Yeh CC, Lee C, Dahiya R,. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem Biophys Res Commun 2001; 285: 409-413.
41. Mastrocola AS, Heinen CD,. Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage. DNA Repair 2010; 9 (2): 120-133.
42. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA,. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61 (13): 5193-5201.
43. Strom SS, Spitz MR, Yamamura Y, Babaian RJ, Scardino PT, Wei Q,. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: A case-control study. Prostate 2001; 47 (4): 269-275.
44. Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK, Watson DK, Schweinfest CW,. Defects of DNA mismatch repair in human prostate cancer. Cancer Res 2001; 61 (10): 4112-4121.
45. Soni A, Bansal A, Singh LC, Mishra AK, Majumdar M, Regina T, Mohanty NK, Saxena S,. Gene expression profile and mutational analysis of DNA mismatch repair genes in carcinoma of prostate in Indian population. OMICS 2011; 15 (5): 319-324.
46. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG,. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64 (60): 1975-1986.
47. Topping RP, Wilkinson JC, Scarpinato KD,. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem 2009; 284 (21): 14029-14039.
48. Ruzov A, Shorning B, Mortusewicz O, Dunican DS, Leonhardt H, Meehan RR,. MBD4 and MLH1 are required for apoptotic induction in xDNMT1-depleted embryos. Development 2009; 136 (13): 2277-2286.
49. Screaton RA, Kiessling S, Sansom OJ, Millar CB, Maddison K, Bird A, Clarke AR, Frisch SM,. Fa-associated death domain protein interacts with methyl-CpG binding domain 4: A potential link between genome survelliance and apoptosis. Proc Natl Acad Sci USA 2003; 100 (9): 5211-5216.